
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is poised for long-term growth primarily driven by its HIV business, with a notable PrEP-to-need ratio increase from 10 in 2021 to approximately 14, indicating a growing demand for preventative therapies. The upcoming approval of LEN for PrEP, with a PDUFA date set for June 19, 2025, is anticipated to be a critical component in enhancing the company's revenue streams. Additionally, promising data from the ASCENT-03 trial for Trodelvy could significantly expand its market by potentially doubling the eligible patient population for the therapy, further bolstering Gilead's oncology portfolio.
Bears say
The financial outlook for Gilead Sciences appears negative primarily due to the lower than anticipated uptake of lenacapavir in HIV pre-exposure prophylaxis (PrEP), leading to non risk-adjusted peak sales projected to be below $4 billion. Additionally, while proposed cuts to government funding for HIV programs are not expected to substantially impact Gilead's HIV franchise, the company is concerned about maintaining the high efficacy standards set by its leading product, Biktarvy, which may complicate future product development. Overall, these factors combined contribute to a bleak financial perspective for Gilead as it navigates both its existing portfolio and expansion into oncology.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares